{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:53Z","timestamp":1791704813675,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Current Research funds"],"award-info":[{"award-number":["Current Research funds"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.103013","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:48:27Z","timestamp":1788612507000},"page":"103013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dinutuximab beta with TEMIRI chemotherapy in relapsed\/refractory neuroblastoma: Real-world insights into the open question of GD2 expression"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-4505","authenticated-orcid":false,"given":"Maria Antonietta","family":"De Ioris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9028-7767","authenticated-orcid":false,"given":"Valentina","family":"Bertaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-4410","authenticated-orcid":false,"given":"Francesco","family":"Fabozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iside","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-6121","authenticated-orcid":false,"given":"Maria Felicia","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Stracuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Altini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-8998","authenticated-orcid":false,"given":"Matilde","family":"Sinibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-9261","authenticated-orcid":false,"given":"Stefano","family":"Di Cecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Becilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Crocoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cassanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Margaritora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.103013_bib0001","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0002","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/cncr.30934","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0003","first-page":"1","article-title":"High-risk and relapsed neuroblastoma: toward more cures and better outcomes","volume":"42","author":"DuBois","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.tranon.2026.103013_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","article-title":"Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children\u2019s Oncology Group study","volume":"29","author":"Bagatell","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0005","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","article-title":"Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children\u2019s Oncology Group study","volume":"28","author":"London","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0006","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2013.08.012","article-title":"Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study","volume":"50","author":"Di Giannatale","year":"2014","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.tranon.2026.103013_bib0007","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10025","article-title":"Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan\/temozolomide\/dinutuximab\/granulocyte-macrophage colony-stimulating factor","author":"Lerman","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0009","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO-25-01868","article-title":"Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON immuno phase II trial","volume":"44","author":"Gray","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10002","volume":"40","author":"Gray","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0011","series-title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","author":"Roussy","year":"2025"},{"key":"10.1016\/j.tranon.2026.103013_bib0012","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting","volume":"35","author":"Park","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00259-017-3829-7","article-title":"Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN\/HR-NBL1 and COG-A3973 trials","volume":"45","author":"Ladenstein","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2026.103013_bib0014","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1002\/cncr.34445","article-title":"Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Act. Dermosifiliogr."},{"key":"10.1016\/j.tranon.2026.103013_bib0016","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.tranon.2026.103013_bib0017","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103013_bib0018","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01630","article-title":"Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: a multicenter, phase I\/II trial","author":"Flaadt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0019","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.103013_bib0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.103013_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31831","article-title":"Accelerating drug development for neuroblastoma: consensus statement from the third neuroblastoma drug development strategy forum","volume":"72","author":"DuBois","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.23.00458","article-title":"Bevacizumab, irinotecan, or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON-neuroblastoma trial","volume":"42","author":"Moreno","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.21.01916","article-title":"When innovation and commercialization collide: a patient advocate view in neuroblastoma","volume":"40","author":"Bird","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1082771","article-title":"Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma","volume":"13","author":"Wieczorek","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1041443","article-title":"Dinutuximab beta plus conventional chemotherapy for relapsed\/refractory high-risk neuroblastoma: a single-center experience","volume":"12","author":"Olgun","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.103013_bib0026","article-title":"Chemo-immunotherapy with dinutuximab beta in patients with relapsed\/progressive high-risk neuroblastoma: does chemotherapy backbone matter?","volume":"202","author":"Raiser","year":"2024","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.tranon.2026.103013_bib0027","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.21037\/qims-24-1251","article-title":"The value of 123I-MIBG xSPECT\/CT quantitative parameters in the diagnosis of bone metastasis in pediatric neuroblastoma patients","volume":"15","author":"Wang","year":"2025","journal-title":"Quant. Imaging Med. Surg."},{"key":"10.1016\/j.tranon.2026.103013_bib0028","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/cancers13061264","article-title":"Clinical and pathological evidence of anti-gd2 immunotherapy induced differentiation in relapsed\/refractory high-risk neuroblastoma","volume":"13","author":"Mora","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.103013_bib0029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/pbc.26184","article-title":"Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence","volume":"64","author":"Schumacher-Kuckelkorn","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1093526617723972","article-title":"Expression of disialoganglioside (GD2) in neuroblastic tumors: a prognostic value for patients treated with anti-GD2 immunotherapy","volume":"21","author":"Terzic","year":"2018","journal-title":"Pediatr. Dev. Pathol."},{"key":"10.1016\/j.tranon.2026.103013_bib0031","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1382931","article-title":"Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells","volume":"15","author":"Di Matteo","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.103013_bib0033","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7051","article-title":"Current and Emerging Biomarkers: impact on Risk Stratification for Neuroblastoma","volume":"22","author":"Irwin","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.tranon.2026.103013_bib0034","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/jcm12196223","article-title":"A multi-color flow cytometric assay for quantifying dinutuximab binding to neuroblastoma cells in tumor, bone marrow, and blood","volume":"12","author":"Keyel","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tranon.2026.103013_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf008","article-title":"Detection of plasma circulating GD2 ganglioside in patients with neuroblastoma and age-matched healthy children. Diagnostic and prognostic evaluation","volume":"30","author":"Morini","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.103013_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2021.12.007","article-title":"Age-dependent reference intervals in children for the disialoganglioside, GD2, a circulating tumor biomarker for the childhood cancer, neuroblastoma","volume":"101","author":"Busch","year":"2022","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.tranon.2026.103013_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28031","article-title":"The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma","volume":"67","author":"Balis","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.103013_bib0038","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13046-025-03481-w","article-title":"Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma \u2013 a multi-center study","volume":"44","author":"Gelineau","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:29:38Z","timestamp":1791703778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S1936523326003499"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103013","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dinutuximab beta with TEMIRI chemotherapy in relapsed\/refractory neuroblastoma: Real-world insights into the open question of GD2 expression","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103013"}}